SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Board appointment

12 Nov 2015 07:00

RNS Number : 4321F
Silence Therapeutics PLC
12 November 2015
 



 

 

 

Board appointment

12th November 2015

 

Silence Therapeutics plc

 

 

Silence Therapeutics plc, AIM: SLN ('Silence' or 'the Company'), a leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, is pleased to announced the appointment of Alistair Gray as Non-Executive Director of the Company, with immediate effect. Alistair will also Chair the Audit Committee.

 

Alistair brings with him a wealth of consultancy and business experience. Having trained as an accountant, his early career was in senior management positions with Unilever and John Wood Group PLC. Alistair was a Director of Arthur Young (now Ernst and Young) Management Consultants and PA Consulting Group. Alistair founded Genesis Consulting and, most recently, Renaissance & Company, a strategic management consultancy working with clients across business and sport.

 

Alistair has served as Executive Chairman of the Winning Scotland Foundation and previously served as Chair of British Swimming and British Basketball, leading significant change in both sports. Alistair is currently Chairman of Edrington's Pension Trustees, responsible for management of a major private pension fund and also Chair of the trading division of John Hogg & Company. Alistair chaired the Audit and Remuneration committees of AorTech International PLC and Highland Distillers PLC, as well as the Pension Trustee Board. Alistair also served as a Fellow of the Institute of Directors and Institute of Consultants.

 

 

Stephen Parker Ph.D.  Non-Executive Chairman of Silence Therapeutics, said:

"We are delighted to welcome Alistair to the Board of Silence Therapeutics. His expertise in strategic leadership will be invaluable as we continue to expand our business and seek to deliver value to our shareholders."

 

 

Alistair William Gray, age 67, holds no shares in the Company. He holds or has held the following directorships within the last five years:

 

Current

Renaissance & Company Limited

 

Past

Winning Scotland Foundation (formerly The Scottish Institute of Sport Foundation)

British Swimming Limited

High Performance Swimming Limited

pmpgenesis Limited

Genesis Consulting Limited - dissolved

Genesis Research Limited - dissolved

Genesis Subsidiary Limited - dissolved

Genesis Red Limited - dissolved

 

Genesis Consulting Ltd, a company founded in 1992 by Alistair Gray was put into compulsory liquidation in February 2010. The associated companies were also dissolved.

 

Save as set out above, there are no further disclosures pursuant to paragraph (g) of Schedule 2 of the AIM Rules.

 

 

 

Enquiries:

 

Silence Therapeutics plc

Ali Mortazavi, Chief Executive Officer

Timothy Freeborn, Chief Financial Officer

Tel: +44 (0)20 3457 6900

 

Canaccord Genuity Limited (Nominated Adviser and Joint Broker)

Dr Julian Feneley/Henry Fitzgerald-O'Connor/Emma Gabriel

Tel: +44 (0)20 7523 8350

 

 

Peel Hunt LLP (Joint Broker)

James Steel/Dr Tom Burt/Oliver Jackson

 

Tel: +44 (0)20 7418 8900

Media Enquiries:

FTI Consulting

Simon Conway/Brett Pollard/Stephanie Cuthbert

Tel: +44 (0) 20 3727 1000

 

 

 

 

Notes to Editors

 

About Silence Therapeutics plc

Our technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. This technology can selectively silence or replace any gene in the genome, modulating gene expression up as well as down in a variety of organs and cell types, in vivo.

We have developed proprietary modifications to improve the robustness of RNA sequences, together with advanced liposomal chemistries to enhance the delivery of therapeutics. This allows the development of therapeutics for diseases with high unmet medical need. In 2015 Silence announced interim results from a Phase 2a pancreatic cancer trial using its compound, Atu027, in combination with gemcitabine.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAGMMMMMMKGKZZ
Date   Source Headline
17th May 20115:39 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
17th May 20115:38 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
17th May 20115:38 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
16th May 20113:36 pmPRNGrant of options and warrants
16th May 20112:30 pmPRNResult of General Meeting
16th May 20117:00 amPRNResults of Placing and Open Offer
12th May 20115:42 pmPRNTR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES
27th Apr 20117:06 amPRNPlacing and Open Offer of New Ordinary Shares
27th Apr 20117:01 amPRNFull Year Results for the Year Ended 31 December 2010
26th Apr 20114:40 pmRNSSecond Price Monitoring Extn
26th Apr 20114:35 pmRNSPrice Monitoring Extension
7th Apr 20114:40 pmRNSSecond Price Monitoring Extn
7th Apr 20114:35 pmRNSPrice Monitoring Extension
7th Apr 20111:37 pmRNSTR-1: Notification of Major Interest in Shares
4th Apr 20114:40 pmRNSSecond Price Monitoring Extn
4th Apr 20114:35 pmRNSPrice Monitoring Extension
21st Mar 20118:00 amRNSPF-04523655 Phase 2 Study Results
14th Feb 20114:35 pmRNSPrice Monitoring Extension
7th Feb 20117:00 amRNSOffer Update
21st Dec 20107:00 amRNSYear-end Update
17th Nov 20104:40 pmRNSSecond Price Monitoring Extn
17th Nov 20104:35 pmRNSPrice Monitoring Extension
16th Nov 20104:40 pmRNSSecond Price Monitoring Extn
16th Nov 20104:35 pmRNSPrice Monitoring Extension
15th Nov 20104:40 pmRNSSecond Price Monitoring Extn
15th Nov 20104:35 pmRNSPrice Monitoring Extension
12th Nov 20102:53 pmPRNForm 8.3 - Silence Therapeutics Plc
12th Nov 20101:35 pmBUSForm 8.3 - Silence Therapeutics plc
11th Nov 20101:54 pmPRNForm 8.3 - Silence Therapeutics Plc
11th Nov 201011:49 amRNSHolding in Company
11th Nov 20107:28 amBUSForm 8.3 - Silence Therapeutics plc
5th Nov 20104:40 pmRNSSecond Price Monitoring Extn
5th Nov 20104:35 pmRNSPrice Monitoring Extension
22nd Oct 20107:53 amBUSForm 8.3 - Silence Therapeutics plc
21st Oct 20109:23 amBUSForm 8.3 - Silence Therapeutics plc
20th Oct 20104:40 pmRNSSecond Price Monitoring Extn
20th Oct 20104:40 pmRNSSecond Price Monitoring Extn
20th Oct 20104:35 pmRNSPrice Monitoring Extension
20th Oct 20104:35 pmRNSPrice Monitoring Extension
20th Oct 20103:35 pmBUSForm 8.3 - Silence Therapeutics plc
20th Oct 20107:00 amRNSSilence Therapeutics Receives European RNAi Patent
19th Oct 20101:21 pmBUSForm 8.3 - Silence Therapeutics plc
18th Oct 20104:40 pmRNSSecond Price Monitoring Extn
18th Oct 20104:35 pmRNSPrice Monitoring Extension
15th Oct 20104:27 pmBUSForm 8.3 - Silence Therapeutics plc - Replacement
15th Oct 20104:27 pmBUSForm 8.3 - Silence Therapeutics plc - Replacement
15th Oct 20102:28 pmBUSForm 8.3 - Silence Therapeutics plc
15th Oct 20101:52 pmBUSForm 8.3 - Silence Therapeutics plc
12th Oct 20104:35 pmRNSPrice Monitoring Extension
11th Oct 20105:04 pmBUSForm 8.3 - Silence Therapeutics plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.